Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. | ClinicLens
To evaluate the safety, efficacy and immunogenicity of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema who completed the 52-week global phase III trial and were enrolled in an extension study. In a 20-week, multicentre, open-label extension study a
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.